Welcome to the island of misfit toys. While everyone is obsessing over Big Tech fighting for the AI crown, this random collection of edge hardware suppliers, gold hedges, and literal zombie companies is staging a thoroughly ridiculous show in 2026. This is stupid and here is why: we have real businesses printing cash off the AI boom sitting right next to micro-caps struggling to stay listed. The market is completely schizophrenic.

AXT (AXTI.US) is riding the AI networking wave hard. Their Q2 2026 revenue doubled year-over-year to USD 47.6M, and they locked in an USD 87.5M capacity agreement for indium phosphide substrates with Lumentum. The stock saw a massive pop in August before investors took profits. Forget the daily noise; as long as the AI infrastructure build-out continues, their business is essential.

indie Semiconductor (INDI.US) is another edge AI player grabbing its slice of the pie. They posted a solid Q2 2026 with USD 64M in revenue, up 24% year-over-year, targeting auto and humanoid robots. The stock surged post-earnings. But the CFO selling shares in July right before the good news? That is not a great look. Why aren't you holding your own equity if the future is so bright?

Whenever the tech market feels too frothy, people run to shiny rocks. iShares Gold Trust Micro (IAUM.US) and Direxion Daily Gold Miners Index Bull 2X Shares (NUGT.US) are basically anxiety thermometers. NUGT even did a reverse split earlier this year. If you need 2x leverage on gold miners in 2026, you are just gambling.

For those needing a blood pressure pill, PIMCO Corporate & Income Opportunity Fund (PTY.US) is the reliable boomer income play. PIMCO is expanding this fund's mandate to include more derivatives starting late August. They keep paying their monthly dividends. Meanwhile, as South Korea launches a semiconductor equipment fund to defend its turf, the Franklin FTSE South Korea ETF (FLKR.US) does the job if you want exposure to that region's chip supply chain without picking winners.

Then we have the absolute junk. Formerly Dunxin Financial, Eason Technology (DXF.US) is drowning in delisting warnings from the NYSE, buying commercial real estate in Hubei, and somehow pivoting into energy venture funds in 2026. Management bought a handful of ADRs in June to look confident. Good luck with that. It looks exactly like the playbook of a desperate company delaying the inevitable. Formerly Wunong Net, Meiwu Technology (WNW.US) executed a frustrating 1-for-100 reverse stock split in April. These listing life-support maneuvers are exhausting. Genprex (GENB.US), a clinical-stage gene therapy company, has absolute radio silence in the news cycle, and in the biotech casino, no news is usually terrible news. As for CynergisTek (COHC.US), this cybersecurity firm was acquired and taken private back in 2022. If this ticker is still on your screen today, your trading terminal needs a serious reboot.

This mix perfectly encapsulates the 2026 market: a blender of legitimate AI infrastructure plays, macro fear-mongering, and pure trash. Know what you are holding, and stop pretending the zombies will come back to life.

This article does not constitute investment advice.